-
公开(公告)号：US20120065148A1
公开(公告)日：2012-03-15
申请号：US13320283
申请日：2010-05-11
IPC分类号： A61K38/02 , C07H21/00 , C07K16/40 , A61P35/00 , C12Q1/68 , C40B30/04 , C07H21/04 , C07H21/02 , C12N9/22 , G01N33/574
CPC分类号： G01N33/68 , C12N9/16 , C12N15/1137 , C12N15/115 , C12N2310/113 , C12N2310/14 , C12N2310/141 , C12N2310/16 , C12Q1/44 , C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Y301/04017 , G01N33/57434 , G01N2333/916 , G01N2800/52 , G01N2800/54 , Y10S436/813
摘要： The present invention relates to phosphodiesterase 4D7 (PDE4D7) for use as a marker for prostate cancer, and the use of PDE4D7 as a marker for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer. The present invention also relates to a composition for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer, a corresponding method and immunoassay, a method for diagnosing, monitoring or prognosticating hormone-resistant prostate cancer vs. hormone-sensitive prostate cancer, a corresponding immunoassay, a method of data acquisition, an immunoassay for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer, a method of identifying an individual for eligibility for prostate cancer therapy, an immunoassay for stratifying an individual or cohort of individuals with a prostate cancer disease, an immunoassay for stratifying an individual with prostate cancer, as well as a pharmaceutical composition comprising a compound directly stimulating or modulating the activity of PDE4D7, a compound indirectly stimulating or modulating the activity of PDE4D7, the PDE4D7 protein or a biologically active equivalent thereof, a nucleic acid encoding and expressing PDE4D7, a miRNA inhibitor specific for PDE4D7 miRNAs, a demethylation agent and/or a phosphodiesterase displacement factor.
摘要翻译： 本发明涉及用作前列腺癌标志物的磷酸二酯酶4D7（PDE4D7），以及使用PDE4D7作为诊断，检测，监测或预测前列腺癌或前列腺癌进展的标志物。 本发明还涉及用于诊断，检测，监测或预测前列腺癌或前列腺癌进展的组合物，相应的方法和免疫测定，用于诊断，监测或预测激素抵抗性前列腺癌与激素敏感前列腺的方法 癌症，相应的免疫测定，数据采集方法，用于诊断，检测，监测或预测前列腺癌的免疫测定或前列腺癌的进展，鉴定个体对前列腺癌治疗的资格的方法，用于分层个体的免疫测定 或具有前列腺癌疾病的个体队列，用于分层患有前列腺癌的个体的免疫测定，以及包含直接刺激或调节PDE4D7活性的化合物的药物组合物，间接刺激或调节PDE4D7活性的化合物 PDE4D7蛋白或生物学 其活性成分，编码并表达PDE4D7的核酸，PDE4D7 miRNA特异性的miRNA抑制剂，去甲基化剂和/或磷酸二酯酶置换因子。
-
公开(公告)号：US09828604B2
公开(公告)日：2017-11-28
申请号：US13320446
申请日：2010-05-11
IPC分类号： C12Q1/68 , C12N15/113 , C12N9/16 , G01N33/574
CPC分类号： C12N15/1137 , C12N9/16 , C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , G01N33/57434 , G01N2800/52
摘要： The present invention relates to phosphodiesterase 9A (PDE9A) for use as a marker for prostate cancer, and the use of PDE9A as a marker for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer. The present invention also relates to a composition for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer, a corresponding method and immunoassay, a method for diagnosing, monitoring or prognosticating hormone-resistant prostate cancer vs. hormone-sensitive prostate cancer, a corresponding immunoassay, a method of data acquisition, an immunoassay for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer, a method of identifying an individual for eligibility for prostate cancer therapy, an immunoassay for stratifying an individual or cohort of individuals with a prostate cancer disease, an immunoassay for stratifying an individual with prostate cancer. The present invention further envisages pharmaceutical compositions and their use for the treatment of prostate cancer, in particular hormone-resistant prostate cancer.
-
公开(公告)号：US08753892B2
公开(公告)日：2014-06-17
申请号：US13320283
申请日：2010-05-11
IPC分类号： G01N33/68
CPC分类号： G01N33/68 , C12N9/16 , C12N15/1137 , C12N15/115 , C12N2310/113 , C12N2310/14 , C12N2310/141 , C12N2310/16 , C12Q1/44 , C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Y301/04017 , G01N33/57434 , G01N2333/916 , G01N2800/52 , G01N2800/54 , Y10S436/813
摘要： The present invention relates to phosphodiesterase 4D7 (PDE4D7) for use as a marker for prostate cancer, and the use of PDE4D7 as a marker for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer. The present invention also relates to a composition for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer, a corresponding method and immunoassay, a method for diagnosing, monitoring or prognosticating hormone-resistant prostate cancer vs. hormone-sensitive prostate cancer, a corresponding immunoassay, a method of data acquisition, an immunoassay for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer, a method of identifying an individual for eligibility for prostate cancer therapy, an immunoassay for stratifying an individual or cohort of individuals with a prostate cancer disease, an immunoassay for stratifying an individual with prostate cancer, as well as a pharmaceutical composition comprising a compound directly stimulating or modulating the activity of PDE4D7, a compound indirectly stimulating or modulating the activity of PDE4D7, the PDE4D7 protein or a biologically active equivalent thereof, a nucleic acid encoding and expressing PDE4D7, a miRNA inhibitor specific for PDE4D7 miRNAs, a demethylation agent and/or a phosphodiesterase displacement factor.
摘要翻译： 本发明涉及用作前列腺癌标志物的磷酸二酯酶4D7（PDE4D7），以及使用PDE4D7作为诊断，检测，监测或预测前列腺癌或前列腺癌进展的标志物。 本发明还涉及用于诊断，检测，监测或预测前列腺癌或前列腺癌进展的组合物，相应的方法和免疫测定，用于诊断，监测或预测激素抵抗性前列腺癌与激素敏感前列腺的方法 癌症，相应的免疫测定，数据采集方法，用于诊断，检测，监测或预测前列腺癌的免疫测定或前列腺癌的进展，鉴定个体对前列腺癌治疗的资格的方法，用于分层个体的免疫测定 或具有前列腺癌疾病的个体队列，用于分层患有前列腺癌的个体的免疫测定，以及包含直接刺激或调节PDE4D7活性的化合物的药物组合物，间接刺激或调节PDE4D7活性的化合物 PDE4D7蛋白或生物学 其活性成分，编码并表达PDE4D7的核酸，PDE4D7 miRNA特异性的miRNA抑制剂，去甲基化剂和/或磷酸二酯酶置换因子。
-
4.发明授权Phosphodiesterase 4D7 as marker for malignant, hormone-sensitive prostate cancer 有权磷酸二酯酶4D7作为恶性，激素敏感性前列腺癌的标志物公开(公告)号：US08778621B2
公开(公告)日：2014-07-15
申请号：US13320050
申请日：2010-05-11
IPC分类号： G01N33/574
CPC分类号： C12Q1/6886 , C12N9/16 , C12N15/1137 , C12N15/115 , C12N2310/11 , C12N2310/14 , C12N2310/16 , C12Q1/44 , C12Q2600/106 , C12Q2600/112 , C12Q2600/158 , C12Y301/04017 , G01N33/57434 , G01N2800/52
摘要： The present invention relates to phosphodiesterase 4D7 (PDE4D7) for use as a marker for malignant, hormone-sensitive prostate cancer, wherein the expression of the marker is increased when comparing the expression in malignant, hormone-sensitive prostate cancer tissue, to the expression in normal tissue or benign prostate tumor tissue, and the use of PDE4D7 as a diagnostic marker for malignant, hormone-sensitive prostate cancer. The present invention also relates to a composition for diagnosing, detecting, monitoring or prognosticating malignant, hormone-sensitive prostate cancer, a corresponding detection method, a method allowing to discriminate between a benign and malignant hormone-sensitive prostate cancer and a method of data acquisition, as well as corresponding immunoassays. The present invention also relates to a method of identifying an individual for eligibility for malignant, hormone-sensitive prostate cancer as well as an immunoassay for stratifying an individual with such prostate cancer. The present invention further envisages pharmaceutical compositions and their use for the treatment of malignant, hormone-sensitive prostate cancer.
摘要翻译： 本发明涉及用作恶性，激素敏感性前列腺癌的标记物的磷酸二酯酶4D7（PDE4D7），其中当将恶性，激素敏感性前列腺癌组织中的表达与恶性，激素敏感性前列腺癌组织中的表达比较时，标志物的表达增加 正常组织或良性前列腺肿瘤组织，并使用PDE4D7作为恶性，激素敏感性前列腺癌的诊断标记。 本发明还涉及用于诊断，检测，监测或预测恶性，激素敏感性前列腺癌的组合物，相应的检测方法，允许区分良性和恶性激素敏感性前列腺癌的方法和数据采集方法 ，以及相应的免疫测定。 本发明还涉及鉴定个体对恶性，激素敏感性前列腺癌的资格的方法以及用这种前列腺癌分层个体的免疫测定法。 本发明进一步设想药物组合物及其用于治疗恶性，激素敏感性前列腺癌的用途。
-
公开(公告)号：US20120065100A1
公开(公告)日：2012-03-15
申请号：US13320446
申请日：2010-05-11
IPC分类号： G01N33/574 , C07H21/00 , C07K16/40 , C07H21/02 , C40B30/04 , C07H21/04 , A61P35/00 , C12N9/22 , C12Q1/68
CPC分类号： C12N15/1137 , C12N9/16 , C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , G01N33/57434 , G01N2800/52
摘要： The present invention relates to phosphodiesterase 9A (PDE9A) for use as a marker for prostate cancer, and the use of PDE9A as a marker for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer. The present invention also relates to a composition for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer, a corresponding method and immunoassay, a method for diagnosing, monitoring or prognosticating hormone-resistant prostate cancer vs. hormone-sensitive prostate cancer, a corresponding immunoassay, a method of data acquisition, an immunoassay for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer, a method of identifying an individual for eligibility for prostate cancer therapy, an immunoassay for stratifying an individual or cohort of individuals with a prostate cancer disease, an immunoassay for stratifying an individual with prostate cancer. The present invention further envisages pharmaceutical compositions and their use for the treatment of prostate cancer, in particular hormone-resistant prostate cancer.
摘要翻译： 本发明涉及用作前列腺癌的标记物的磷酸二酯酶9A（PDE9A），以及使用PDE9A作为诊断，检测，监测或预测前列腺癌或前列腺癌进展的标志物。 本发明还涉及用于诊断，检测，监测或预测前列腺癌或前列腺癌进展的组合物，相应的方法和免疫测定，用于诊断，监测或预测激素抵抗性前列腺癌与激素敏感前列腺的方法 癌症，相应的免疫测定，数据采集方法，用于诊断，检测，监测或预测前列腺癌的免疫测定或前列腺癌的进展，鉴定个体对前列腺癌治疗的资格的方法，用于分层个体的免疫测定 或患有前列腺癌疾病的个体的群体，用于对患有前列腺癌的个体进行分层的免疫测定。 本发明进一步设想药物组合物及其用于治疗前列腺癌，特别是激素抗性前列腺癌的用途。
-
6.发明申请PHOSPHODIESTERASE 4D7 AS MARKER FOR MALIGNANT, HORMONE-SENSITIVE PROSTATE CANCER 有权PHOSPHODIESTERASE 4D7作为恶性肿瘤标志物，敏感性前列腺癌公开(公告)号：US20120129788A1
公开(公告)日：2012-05-24
申请号：US13320050
申请日：2010-05-11
IPC分类号： A61K38/17 , G01N33/574 , C12Q1/68 , A61P35/00 , C07K16/40 , C12Q1/44 , G01N33/573 , C07H21/02 , C12N9/16 , C07H21/00
CPC分类号： C12Q1/6886 , C12N9/16 , C12N15/1137 , C12N15/115 , C12N2310/11 , C12N2310/14 , C12N2310/16 , C12Q1/44 , C12Q2600/106 , C12Q2600/112 , C12Q2600/158 , C12Y301/04017 , G01N33/57434 , G01N2800/52
摘要： The present invention relates to phosphodiesterase 4D7 (PDE4D7) for use as a marker for malignant, hormone-sensitive prostate cancer, wherein the expression of the marker is increased when comparing the expression in malignant, hormone-sensitive prostate cancer tissue, to the expression in normal tissue or benign prostate tumor tissue, and the use of PDE4D7 as a diagnostic marker for malignant, hormone-sensitive prostate cancer. The present invention also relates to a composition for diagnosing, detecting, monitoring or prognosticating malignant, hormone-sensitive prostate cancer, a corresponding detection method, a method allowing to discriminate between a benign and malignant hormone-sensitive prostate cancer and a method of data acquisition, as well as corresponding immunoassays. The present invention also relates to a method of identifying an individual for eligibility for malignant, hormone-sensitive prostate cancer as well as an immunoassay for stratifying an individual with such prostate cancer. The present invention further envisages pharmaceutical compositions and their use for the treatment of malignant, hormone-sensitive prostate cancer.
摘要翻译： 本发明涉及用作恶性，激素敏感性前列腺癌的标记物的磷酸二酯酶4D7（PDE4D7），其中当将恶性，激素敏感性前列腺癌组织中的表达与恶性，激素敏感性前列腺癌组织中的表达比较时，标志物的表达增加 正常组织或良性前列腺肿瘤组织，并使用PDE4D7作为恶性，激素敏感性前列腺癌的诊断标记。 本发明还涉及用于诊断，检测，监测或预测恶性，激素敏感性前列腺癌的组合物，相应的检测方法，允许区分良性和恶性激素敏感性前列腺癌的方法和数据采集方法 ，以及相应的免疫测定。 本发明还涉及鉴定个体对恶性，激素敏感性前列腺癌的资格的方法以及用这种前列腺癌分层个体的免疫测定法。 本发明进一步设想药物组合物及其用于治疗恶性，激素敏感性前列腺癌的用途。
-
公开(公告)号：US08946580B2
公开(公告)日：2015-02-03
申请号：US13139208
申请日：2009-12-04
申请人： Ralf Hoffmann , Matthias Kroeker
发明人： Ralf Hoffmann , Matthias Kroeker
CPC分类号： H01H1/54 , H01H1/20 , H01H9/443 , H01H50/546 , H01H2001/545
摘要： The present invention relates to contactors for unidirectional DC operation with permanent magnetic arc extinguishing. In addition to the blow magnets, the contactors are equipped with compensatory permanent magnets for compensating the magnetic field in the vicinity of the contact bridge in order to prevent contact levitation, i.e., an uncontrolled opening of the contacts that is due to a magnetic force generated by a strong current flowing through the contact bridge. To this end, the compensatory permanent magnets are arranged in the vicinity of the contact bridge and polarized in the opposite direction of the blow magnets. The magnetic field of the compensatory magnets and the current flowing through the contact bridge are generating a magnetic force that acts on the contact bridge and tends to keep the electrical contacts closed.
摘要翻译： 本发明涉及用于具有永久磁性灭弧的单向直流操作的接触器。 除了吹制磁体之外，接触器还配备有补偿永磁体，用于补偿接触桥附近的磁场，以防止接触悬浮，即由于产生的磁力引起的触头的不受控的打开 通过流过接触桥的强电流。 为此，补偿永久磁铁布置在接触桥附近，并沿着吹塑磁体的相反方向极化。 补偿磁体的磁场和流过接触桥的电流产生作用在接触桥上的磁力，并且趋向于保持电触点闭合。
-
公开(公告)号：US20140309161A1
公开(公告)日：2014-10-16
申请号：US14128083
申请日：2012-06-20
CPC分类号： C07K14/43572 , A01N25/22 , A01N37/46 , A01N63/02 , A61K38/00 , A61K38/10 , A61K38/16 , A61K38/1767 , A61K47/60 , C07K7/08 , C07K11/00 , C07K14/43563 , C12Q1/37
摘要： The invention relates to modified antibiotic peptides, in particular derivatives of apidaecin and oncocin, preferably having increased stability, reduced immunoreaction, and improved pharmacokinetics. In the invention, the peptide antibiotics are reversibly protected by means of a linker having the polymer polyethylene glycol (PEG). The peptide linker contains a recognition sequence for trypsin-like serum proteases. In the apidaecin derivatives, the linker and the PEG are bonded to a side chain. In the serum, the linker is cut by serum proteases and PEG is separated off. The released peptide still contains remnants of the linker, which are still bonded to the amino group in the side chain. Astonishingly, said remaining remnants of the linker impair the activity of the antimicrobial peptide only a little or not at all.
摘要翻译： 本发明涉及修饰的抗生素肽，特别是apidaecin和oncocin的衍生物，优选具有增加的稳定性，降低的免疫反应和改善的药代动力学。 在本发明中，肽抗生素通过具有聚合物聚乙二醇（PEG）的接头可逆地保护。 肽接头包含胰蛋白酶样血清蛋白酶的识别序列。 在apidaecin衍生物中，接头和PEG与侧链结合。 在血清中，用血清蛋白酶切割接头，分离出PEG。 释放的肽仍然含有仍然与侧链中的氨基键合的接头残基。 令人惊讶的是，所述接头的剩余残留物仅仅少量地损害了抗微生物肽的活性。
-
公开(公告)号：US08686113B2
公开(公告)日：2014-04-01
申请号：US13147095
申请日：2010-01-29
CPC分类号： C07K7/08 , A01N47/44 , A61K38/00 , A61K38/10 , A61K47/48246 , A61K47/64 , C07K14/43563 , C12Q1/18 , G01N2500/10 , Y02A50/473 , Y02A50/475 , Y02A50/478 , Y02A50/481 , Y02A50/483
摘要： The invention relates to a peptide or peptide derivative having the general formula: Sub1-X1-D2K3-P4-P5-Y6-L7-P8-R9-P10-X2-P12-P13-R14-X3-I16-P17/Y17-N18-N19-X4-Sub2, wherein X1 is a non-polar, hydrophobic group or a positively charged group, D2 is asparagine or glutamine, K3, X2, and X4 are positively charged groups, X3 is a positively charged group, proline, or a proline derivative; L7 and I16 are non-polar, hydrophobic groups, Y6 and Y17 are tyrosine, R9 and R14 are arginine, N18 and N19 are asparagine or glutamine, P4, P5, P8, P10, P12, P13, and P17 are proline, hydroxyproline, or derivatives thereof, wherein possibly one or two of the groups selected from D2, P4, P5, P8, P10, P12, P13, P17, and Y17 are replaced by an arbitrary group and/or P13 and R14 are exchanged, Sub1 is the free or modified N-terminus, and Sub2 is the free or modified C-terminus. The invention further relates to the use of the peptides and peptide derivatives in medicine, as an antibiotic, in a disinfectant or cleaning agent, as a preservative or in a packaging material, in pharmaceutical research, or in a screening method.
摘要翻译： 本发明涉及具有以下通式的肽或肽衍生物：Sub1-X1-D2K3-P4-P5-Y6-L7-P8-R9-P10-X2-P12-P13-R14-X3-I16-P17 / Y17- N18-N19-X4-Sub2，其中X1是非极性疏水基团或带正电荷的基团，D2是天冬酰胺或谷氨酰胺，K 3，X 2和X 4是带正电荷的基团，X 3是带正电荷的基团， 或脯氨酸衍生物; L7和I16是非极性疏水基团，Y6和Y17是酪氨酸，R9和R14是精氨酸，N18和N19是天冬酰胺或谷氨酰胺，P4，P5，P8，P10，P12，P13和P17是脯氨酸，羟脯氨酸， 或其衍生物，其中可选地一个或两个选自D2，P4，P5，P8，P10，P12，P13，P17和Y17的基团被任意基团替代和/或P13和R14被交换，Sub1是 游离或修饰的N末端，Sub2是游离或修饰的C-末端。 本发明还涉及肽和肽衍生物在药物，作为抗生素，在消毒剂或清洁剂中，作为防腐剂或在包装材料中，在药物研究中或在筛选方法中的用途。
-
公开(公告)号：US08050477B2
公开(公告)日：2011-11-01
申请号：US12162671
申请日：2007-01-22
IPC分类号： A61N5/10
CPC分类号： A61N5/1031
摘要： An improved radiation therapy planning procedure is suggested. The procedure comprises the steps of specifying and determining the absolute grade of cell degeneracy by in-vitro tests, whereby marker(s) indicative for specific cell degeneracy are detected and quantified, establishing a biology-based segmentation of areas with similar grade of relative cell degeneracy and applying the absolute grade of cell degeneracy to the biology-based segmentation data, thereby establishing an improved radiation therapy planning procedure. Moreover, the present invention suggests a system for an improved radiation therapy planning procedure and its use in procedures of diagnosis and/or therapy management of cancer.
摘要翻译： 建议采用改进的放射治疗计划程序。 该方法包括以下步骤：通过体外测试来指定和确定细胞退化的绝对等级，由此检测和量化指示特异性细胞退化的标志物，建立具有相似等级的相对细胞的区域的基于生物学的分割 退化并将绝对等级的细胞退化应用于基于生物学的分割数据，从而建立改进的放射治疗计划程序。 此外，本发明提出了一种改进的放射治疗计划程序及其在癌症诊断和/或治疗管理程序中的应用的系统。
-
-
-
-
-
-
-
-
-
搜索结果
77 条记录 (耗时 0.029 秒)
